New Anti-Radiation Pill Could Save Lives!
New anti-radiation pills will decide who lives and dies in the next nuclear war or who will be able to fix the deadly situation in the Fukushima disaster in Japan.
What? You didn't get yours yet? Don' feel bad. The secret new pill, known by the code ON01210.Na, was developed and stockpiled exclusively for the military by Onconova Therapeutics. It called Ex-Rad. Yes, we changed the name in the illustration [above] to avoid hassles. Ex-Rad is a potent agent, protecting cellular DNA from the deadly effects of radiation -- like from a thermo-nuclear bomb. Phase I clinical studies on human volunteers showed no ill side effects. While these were healthy, unradiated humans, the experiments with mice, who received total body exposure to high levels of radiation, shows it dramatically increases the survival rate.
The tests were conducted with the injectable form of the drug, but there is now a chewable tablet that can either be taken before the "radiation event" or up to 4 hours after the blast from the nukes.
Because it has been developed by (among others) the Armed Forces Radiological Research Institute, it is likely that Ex-Rad will be exclusively utilized to protect the same people who potentially initiate nuclear explosions -- so they will survive to fight again.
According to reports we have found, a single dose of Ex-Rad costs about $800 (USD) and can be given either 24 hours before, or 36 hours after exposure to non-lethal radiation (i.e. radiation at levels that would normally kill a person outright). It protects the death of cells that usually occur following non-lethal exposure by allowing the DNA to repair itself.
This kind of therapy would seem to be urgently needed by the citizens of Japan and the US, suffering fallout from the Fukushima reactor meltdowns... Certainly TEPCO should be able to afford giving its workers this life-saving medicine... or are they really that inhumane!
And while we're talking about radiation, how about the Iraq women who are seeing a undeniable rise in stillbirths and mutations due to the depleted uranium someone left in their country? How about our own servicemen who were likewise exposed to DU in Desert Storm? (see www.viewzone.com/du/du.html) I guess not.
From Wikipedia, the free enclclopedia
Ex-Rad (or Ex-RAD), also known by the code name ON 01210.Na, is a drug developed by Onconova Therapeutics and the U.S. Department of Defense. This newly developed compound is said to be a potent radiation protection agent. Chemically, it is the sodium salt of 4-carboxystyryl-4-chlorobenzylsulfone.
Clinical trials The results of two Phase I clinical studies in healthy human volunteers indicate that subcutaneously injected Ex-Rad is safe and well tolerated, with "no evidence of systemic side effects". A study in mice demonstrated the efficacy of Ex-Rad by increasing the survival rate of mice exposed to typically lethal whole-body irradiation. The study tested oral and parenteral administration of Ex-Rad for both pre- and post-exposure radiomitigation.
Research on Ex-Rad has involved collaboration with the Armed Forces Radiobiology Research Institute (AFRRI), the Department of Biochemistry and Molecular & Cellular Biology at Georgetown University, Long Island University's Arnold & Marie Schwartz College of Pharmacy, and the Department of Oncological Sciences at the Mt. Sinai School of Medicine.
Mechanism of action
Onconova suggests that Ex-Rad protects cells exposed to radiation against DNA damage, and that the drug's mechanism of action does not involve scavenging free radicals or arresting the cell cycle. Instead, they claim it employs a "novel mechanism" involving "intracellular signaling, damage sensing, and DNA repair pathways". Ex-RAD is a chlorobenzylsulfone derivative that works after free radicals have damaged DNA.
Onconova CEO Ramesh Kumar believes this is a better approach than trying to scavenge free radicals. "Free radicals are very short-lived, and so the window of opportunity to give a drug is very narrow," he says. In cell and animal models, Ex-RAD protects hematopoietic and gastrointestinal tissues from radiation injury when given either before or after exposure.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells.